Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 967 6677

Website: citiuspharma.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

Idkwhattonamemyself Jul. 27 at 4:09 AM

$CTXR If someone is willing to contact a lawyer and begin filing a class action lawsuit against Citius, I'll gladly join the proceedings.

2 · Reply

Bulltrader988 Jul. 26 at 7:03 PM

$CTXR ownership of $CTOR is now 84.3 % because of the newest offering from $CTOR 👃👀 https://www.sec.gov/Archives/edgar/data/1506251/000121390025067797/xslSCHEDULE_13D_X01/primary_doc.xml

0 · Reply

Noname2022 Jul. 26 at 6:59 PM

$CRMD $CTXR

5 · Reply

Applebat Jul. 26 at 4:36 PM

$CTXR RIP MINO LOK. Mino lok died in spring of 2021 and Leonard has been dragging you all along for the last 4 years. For anyone who has been here that long, go revisit your original investment thesis. This company was all about mino loks potential now the data is in and the whole thing is on the back burner. People here are expecting to get back to 2021 prices with Lymphir, a drug with 1/3 the addressable market that they overpaid for by tens of millions. CTXR literally owns nothing of value now EXCEPT for owning CTOR. and now it owns LESS of that (84% instead of 92%). Mino lok = mino wrap = Halo lido = worthless

1 · Reply

TwongStocks Jul. 25 at 9:04 PM

New 13D filing updates $CTXR ownership stake in $CTOR https://www.sec.gov/Archives/edgar/data/1506251/000121390025067797/xslSCHEDULE_13D_X01/primary_doc.xml After CTOR's recent offering, CTXR now owns 84.3% of CTOR. Down from 92.3% 78,370,402 outstanding shares of CTOR. CTXR owns 66,049,615.

3 · Reply

BALUGA825 Jul. 25 at 4:09 PM

$CTXR $CTOR Staying green as much as possible today is the objective and we enter bulls territory next week. History tends to repeat itself! Back track chart for few weeks and you will see what i am up to.

0 · Reply

DrKyle Jul. 25 at 3:15 PM

$CTOR $CTXR i rest re-entered ctxr and took my entry position in ctor. I held ctxr with mino-lok being the most attractive at the time. Granted my plan didnt go well at the time as all longs recall. My question is in regards to ctxr owning 92% of CTOR and the market caps respectively of each....what am i missing here....?? Thanks

1 · Reply

BALUGA825 Jul. 24 at 6:12 PM

$CTOR Lets close 2 and over... That wil put us on a very well positioned for tomorrow and beyond! $CTXR

1 · Reply

Noname2022 Jul. 24 at 3:03 PM

$CRMD $FMS $DVA $CTXR The more you know: CLABSI - epidemiological definition CBRSI - clinical diagnosis Dialysis patients are: ~1% of federal budget spend ~7% of medicare spending

0 · Reply

God_Damnit Jul. 24 at 1:16 AM

$CTOR $CTXR Banked on CTXR today I hope you sis as well $ORIS looking promising for 4 AM

1 · Reply

Citius Oncology Announces Closing of $9.0 Million Public Offering

CTOR

Jul 16, 2025, 9:15 AM EDT - 12 days ago

Citius Oncology Announces Pricing of $9.0 Million Public Offering

CTOR

Jul 15, 2025, 8:32 AM EDT - 13 days ago

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

CTOR

Jul 8, 2025, 8:34 AM EDT - 20 days ago

Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jun 17, 2025, 8:08 AM EDT - 5 weeks ago

Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025

CTOR

Jun 12, 2025, 8:35 AM EDT - 6 weeks ago

Citius Pharmaceuticals Announces Closing of Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

Jun 10, 2025, 7:00 AM EDT - 6 weeks ago

Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules

May 14, 2025, 4:30 PM EDT - 2 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:37 AM EDT - 3 months ago

Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

CTOR

Apr 1, 2025, 9:00 AM EDT - 4 months ago

Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock

Feb 14, 2025, 4:30 PM EST - 5 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update

CTOR

Feb 6, 2025, 8:55 AM EST - 6 months ago

Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services

CTOR

Jan 8, 2025, 8:00 AM EST - 7 months ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Jan 7, 2025, 8:08 AM EST - 7 months ago

Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025

CTOR

Jan 6, 2025, 7:50 AM EST - 7 months ago

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

CTOR

Dec 27, 2024, 5:00 PM EST - 7 months ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

Nov 25, 2024, 8:03 AM EST - 8 months ago

Citius Pharmaceuticals Reports Productive FDA Type C Meeting to Discuss Phase 3 Mino-Lok® Program and Pathway to Approval

Nov 22, 2024, 9:00 AM EST - 8 months ago

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

Nov 18, 2024, 4:05 PM EST - 9 months ago

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering

Nov 15, 2024, 1:30 PM EST - 9 months ago

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering

Nov 11, 2024, 8:45 AM EST - 9 months ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors

Sep 5, 2024, 4:30 PM EDT - 11 months ago

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:30 AM EDT - 11 months ago

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Aug 12, 2024, 5:28 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:22 PM EDT - 1 year ago

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

Aug 12, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

$Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Aug 8, 2024, 6:59 AM EDT - 1 year ago

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

Jul 18, 2024, 7:00 AM EDT - 1 year ago

Biotech Stocks Race Towards Solutions for Cutaneous T-Cell Lymphoma (CTCL)

Jul 17, 2024, 8:00 AM EDT - 1 year ago

Analysts Hunt for Undervalued Biotech Stocks

Jul 11, 2024, 11:00 AM EDT - 1 year ago

Bloodstream Infections - From Threats to Solutions

Jul 11, 2024, 8:00 AM EDT - 1 year ago

Biopharma Stocks Transformative Innovation for the Future of Health

Jul 10, 2024, 9:10 AM EDT - 1 year ago

Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates

May 29, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

May 21, 2024, 7:00 AM EDT - 1 year ago

Citius Pharmaceuticals Achieves Primary and Secondary Endpoints in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution

May 14, 2024, 4:05 PM EDT - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals to Participate in Upcoming EF Hutton and H.C. Wainwright Investor Conferences

Apr 30, 2024, 4:05 PM EDT - 1 year ago

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

Apr 26, 2024, 8:00 AM EDT - 1 year ago

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

Apr 11, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma

Apr 4, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

$Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Citius Pharmaceuticals Announces FDA Acceptance of the BLA Resubmission of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Mar 7, 2024, 8:30 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Economic Development Program

Feb 26, 2024, 7:30 AM EST - 1 year ago

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

Feb 23, 2024, 8:30 AM EST - 1 year ago

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

Feb 14, 2024, 4:30 PM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

$Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma$

Feb 14, 2024, 8:01 AM EST - 1 year ago

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

Jan 23, 2024, 8:30 AM EST - 1 year ago

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors

Jan 2, 2024, 8:31 AM EST - 1 year ago

Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters

Jan 2, 2024, 8:30 AM EST - 1 year ago

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update

Idkwhattonamemyself Jul. 27 at 4:09 AM

$CTXR If someone is willing to contact a lawyer and begin filing a class action lawsuit against Citius, I'll gladly join the proceedings.

2 · Reply

Bulltrader988 Jul. 26 at 7:03 PM

$CTXR ownership of $CTOR is now 84.3 % because of the newest offering from $CTOR 👃👀 https://www.sec.gov/Archives/edgar/data/1506251/000121390025067797/xslSCHEDULE_13D_X01/primary_doc.xml

0 · Reply

Noname2022 Jul. 26 at 6:59 PM

$CRMD $CTXR

5 · Reply

Applebat Jul. 26 at 4:36 PM

1 · Reply

TwongStocks Jul. 25 at 9:04 PM

3 · Reply

BALUGA825 Jul. 25 at 4:09 PM

0 · Reply

DrKyle Jul. 25 at 3:15 PM

1 · Reply

BALUGA825 Jul. 24 at 6:12 PM

$CTOR Lets close 2 and over... That wil put us on a very well positioned for tomorrow and beyond! $CTXR

1 · Reply

Noname2022 Jul. 24 at 3:03 PM

$CRMD $FMS $DVA $CTXR The more you know: CLABSI - epidemiological definition CBRSI - clinical diagnosis Dialysis patients are: ~1% of federal budget spend ~7% of medicare spending

0 · Reply

God_Damnit Jul. 24 at 1:16 AM

$CTOR $CTXR Banked on CTXR today I hope you sis as well $ORIS looking promising for 4 AM

1 · Reply

Noname2022 Jul. 23 at 11:51 PM

$CTXR

1 · Reply

BALUGA825 Jul. 23 at 10:20 PM

$CTOR We wait till friday with this much green everyday and next week will be blue sky again Backtrack the chart for few weeks and you will see it on both ticker! $CTXR

1 · Reply

HypnoTrader Jul. 23 at 7:11 PM

$CTXR $CTOR I find it confusing that these stocks do not mimic each other's moves. One is almost at day's high, while the other lost most of it gains. Yet ctxr main asset is the 66 million share ctor position. What's up....

1 · Reply

amrelsherbiny Jul. 23 at 4:50 PM

$CTXR I've been holding this stock for over three years now. I kind of lost hope on this stock for some time but wouldn't sell at about 90% loss because it wasn't worth it. For the past month or so since it started rising I started averaging down and today I finally broke even thank God. I now have how that I can finally make money on this after 3 years of holding. Fingers crossed 🤞

2 · Reply

BALUGA825 Jul. 23 at 4:41 PM

$CTOR Clowns came out of nowhere praising dooms day for your money! LoL $CTXR LFG! Bring it. Were about to enter the bulls territory again....

2 · Reply

SweStonk Jul. 23 at 3:13 PM

$CTXR only 2-3 weeks until we see an offering. Gonna load up after the offering 😎

0 · Reply

YouVSYou Jul. 23 at 2:54 PM

$CTOR $CTXR

0 · Reply

SqueezeMagnet Jul. 23 at 2:45 PM

We called $CTOR and $CTXR early ! Same Move will happen to $OLB ... Spin-off play as well .

0 · Reply

God_Damnit Jul. 23 at 2:14 PM

$CTXR gonna go with $CTOR

0 · Reply

RICHARDSTOCK Jul. 23 at 12:21 AM

$CTXR ✋️ to see when they start make profit 📈 👌

0 · Reply

BALUGA825 Jul. 22 at 8:52 PM

$CTOR 1 or 2 more days of this much green and we will enter the bulls territory. $CTXR

0 · Reply

amrelsherbiny Jul. 22 at 7:54 PM

$CTXR

0 · Reply

Market Cap	17.76M
Revenue (ttm)	0.00
Net Income (ttm)	-39.14M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	401,600
Avg Vol	3,218,192
Day's Range	N/A - N/A
Shares Out	10.63M
Stochastic %K	44%
Beta	1.23
Analysts	Sell
Price Target	$6.00